prop-1-en-2-yl N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]carbamate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: prop-1-en-2-yl N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]carbamate
• 化学式: C₁₃H₁₅F₂N₃O₆
• 分子量: 347.27
• InChiKey: JPJKBFSDPCWFSQ-SZEHBUNVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof
  申请人：Gallop A. Mark

  公开号：US20080021208A1

  公开（公告）日：2008-01-24

  The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions of using gemcitabine prodrugs to treat or prevent diseases or disorders such as cancer or viral infections.
• GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Gallop Mark A.

  公开号：US20100016254A1

  公开（公告）日：2010-01-21

  The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions of using gemcitabine prodrugs to treat or prevent diseases or disorders such as cancer or viral infections.
• US7265096B2
  申请人：——

  公开号：US7265096B2

  公开（公告）日：2007-09-04
• US7608602B2
  申请人：——

  公开号：US7608602B2

  公开（公告）日：2009-10-27
• US7803785B2
  申请人：——

  公开号：US7803785B2

  公开（公告）日：2010-09-28